SCHEMBL4414149

SCHEMBL4414149

CN(C)S(=O)(=O)c1ccc2c(c1)C(=NNc1ccccc1[N+](=O)[O-])C(=O)N2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
LMNA P02545 4/20 0.47
GAA P10253 1/20 0.47
HPGD P15428 1/20 0.47
KMT2A Q03164 5/20 0.41
MEN1 O00255 4/20 0.41
POLB P06746 2/20 0.41
VCAM1 P19320 1/20 0.41
PKM P14618 1/20 0.41
KDM4E B2RXH2 1/20 0.41
HTT P42858 1/20 0.41
MAPT P10636 4/20 0.41
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
PTPN11 Q06124 1/20 0.40
CA12 O43570 1/20 0.40
CA9 Q16790 1/20 0.40
MAPK1 P28482 3/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4896187 1.00 ALDH1A1 (0.47) ALDH1A1LMNAGAAHPGDKMT2A
SCHEMBL4903811 0.89 CASP3 (0.48) ALDH1A1LMNAGAAHPGDKMT2A
SCHEMBL4903813 0.89 CASP3 (0.48) ALDH1A1LMNAGAAHPGDKMT2A
SCHEMBL4417241 0.88 PTPN11 (0.45) ALDH1A1HPGDKMT2AMEN1POLB
SCHEMBL29518006 0.88 PTPN11 (0.45) ALDH1A1HPGDKMT2AMEN1POLB
SCHEMBL15896784 0.88 PTPN11 (0.45) ALDH1A1HPGDKMT2AMEN1POLB
SCHEMBL4413416 0.88 CA1 (0.53) ALDH1A1GAAKMT2AMEN1MAPT
SCHEMBL4417242 0.88 PTPN11 (0.45) ALDH1A1HPGDKMT2AMEN1POLB
SCHEMBL4413417 0.88 CA1 (0.53) ALDH1A1GAAKMT2AMEN1MAPT
SCHEMBL14111922 0.85 MGAT1 (0.46) ALDH1A1LMNAGAAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8987474-B2 Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs UNIVERSITY OF SOUTH FLORIDA (US) 2015-03-24 US disclosed
WO-2009135000-A2 INHIBITION OF SHP2/PTPN11 PROTEIN TYROSINE PHOSPHATASE BY NSC-117199 AND ANALOGS H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2009-11-05 WO disclosed
US-20080176309-A1 8-hydroxy-7-(6-sulfonaphthalen-2-yl)diazenyl-quinoline-5-sulfonic acid (NSC-87877); Src homology-2 domains; Noonan syndrome, cancer UNIVERSITY OF SOUTH FLORIDA (US) 2008-07-24 US disclosed
WO-2007117699-A2 INHIBITION OF SHP2/PTPN11 PROTEIN TYROSINE PHOSPHATASE BY NSC-87877, NSC-117199 AND THEIR ANALOGS UNIVERSITY OF SOUTH FLORIDA (US) 2007-10-18 WO disclosed
US-5164404-A HYDRAZONE DERIVATIVES AND THEIR USE NEUROSEARCH A/S (DK) 1992-11-17 US disclosed
EP-0503349-A1 Hydrazone derivatives, their preparation and use NEUROSEARCH A/S (DK) 1992-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176309-A1 8-hydroxy-7-(6-sulfonaphthalen-2-yl)diazenyl-quinoline-5-sulfonic acid (NSC-87877); Src homology-2 domains; Noonan syndrome, cancer PTPN7, PTPN1, PTPN2 ALDH1A1 3859/4885LMNA 4809/4885GAA 1584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.